Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open-Label Study to Evaluate Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Who Are Phosphate Binder Naive or on Phosphate Binders to Optimize Phosphorus Management

NCT04549597 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT04549597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04549597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open-Label Study to Evaluate Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Who Are Phosphate Binder Naive or on Phosphate Binders to Optimize Phosphorus Management
Lead sponsor
Ardelyx
Phase
Phase 4
Overall status
Completed
Start date
November 20, 2020
Completion date
December 1, 2021
Enrollment
333 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease requiring chronic dialysis, hyperphosphatemia